- Home
- HNRG vs ALT Comparison
HNRG vs ALT Comparison
Compare HNRG & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNRG | ALT |
|---|---|---|
| Founded | 1949 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 823.6M | 576.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HNRG | ALT |
|---|---|---|
| Price | $22.42 | $5.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $20.00 | $16.33 |
| AVG Volume (30 Days) | 507.3K | ★ 3.5M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $461,142,000.00 | $20,000.00 |
| Revenue This Year | $18.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.15 | N/A |
| 52 Week Low | $8.37 | $2.90 |
| 52 Week High | $24.70 | $9.59 |
Technical Indicators
Market Signals| Indicator | HNRG | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 61.41 |
| Support Level | $19.02 | $5.03 |
| Resistance Level | $22.63 | $5.83 |
| Average True Range (ATR) | 0.88 | 0.38 |
| MACD | 0.32 | 0.01 |
| Stochastic Oscillator | 76.50 | 47.00 |
Price Performance
Historical ComparisonAbout HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.